- Reference code :
- wf392
- Published date :
-
20 June 2001
- Expired date :
-
05 November 2028
AstraZeneca today received approval to market Zomig® for migraine treatment in Japan - the first, second generation triptan type of medicine to be approved there.
The company made application to market Zomig® to Japan's Ministry of Health, Labour and Welfare in April last year. The approved indication is for the acute treatment of migraine.
Zomig® is taken as a 2.5mg tablet and has an excellent effect in relieving pain at the time of an attack and continuing pain after an attack. It selectively acts on the 5-HT 1B/1D receptor.
Since its first launch in the US in 1997, Zomig® has been marketed in more than 50 countries. It is the top selling second generation triptan and in 2000 had worldwide sales of $237m - an increase of 25 per cent on the previous year.
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of $15.8 billion and leading positions in sales of gastrointestinal, oncology, anaesthesia including pain management, cardiovascular, central nervous system (CNS) and respiratory products.
Further enquires to:
Media RelationsSteve Brown +44 (0)20 7304 5033 Lucy Williams +44 (0)20 7304 5034 |
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 07:01 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
